三生国健药业（上海）股份有限公司 关于与沈阳三生制药有限责任公司签署许可协议暨 关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 证券代码： 688336 证券简称：三生国健 公告编号：2025-005 本次交易构成关联交易，未构成《上市公司重大资产重组管 理办法》规定的重大资产重组。 本次交易实施不存在重大法律障碍。 1 本次关联交易已经公司第五届董事会独立董事专门会议 2025 年第一次会议、第五届董事会第四次会议审议通过，关联董事 LOU JING、苏冬梅回避表决，该事项需提交公司股东大会审议。 对公司业绩的影响：本协议的签订将对公司未来业绩产生积 极影响，有利于提升公司的盈利能力。 本次关联交易为公司正常生产经营需要。以平等互利、相互 协商为合作基础，参考市场公允价格进行协商定价，不存在损害公 司及股东利益的情形，不影响公司的独立性，公司不会因该等关联 交易对关联方产生依赖。 三生国健药业（上海）股份有限公司（以下简称"公司"或 "三生国健"）为进一步聚焦核心优势资产，优化业务结构及资 ...

东 洲评估 三生国健药业( 上海 )股份有限 公司拟向 沈阳 三 生制药有限责任公司转让其持有的部分在研候选 新药管线中国大陆地区独占使用权涉及的部分资 产价值 估值报告 东洲咨报字【2025】第 0261 号 共１册 第１册 上海东 洲资 产评估有限 公司 2025 年 02 月 18 日 中国资产评估协会 资产评估业务报告备案回执 | 报告编码: | 3131020001202500233 | | --- | --- | | 合同编号: | 东洲 咨委(202502124) 号 | | 报告类型: | 估值类咨询报告 | | 报告文号: | 东洲各报字【2025】第 0261 号 | | 报告名称: | 三生国健药业(上海)股份有限公司拟向沈阳三生 制药有限责任公司转让其持有的部分在研候选新药 管线中国大陆地区独占使用权涉及的部分资产价值 | | | 估值报告 | | 评估结论: | 101,900,000.00 元 | | 评估报告日: | 2025年02月18日 | | 评估机构名称: | 上海东洲资产评估有限公司 | | 签名人员: | 许楠(资产评估师) 会员编号:31180022 | | | 潘 ...

三生国健药业（上海）股份有限公司 关于召开 2025 年第一次临时股东大会的通知 证券代码：688336 证券简称：三生国健 公告编号：2025-006 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2025 年第一次临时股东大会 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络 投票相结合的方式 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 3 月 7 日 10 点 00 分 召开地点：中国（上海）自由贸易试验区李冰路 399 号公司会议 室 股东大会召开日期：2025年3月7日 本次股东大会采用的网络投票系统：上海证券交易所股东大 会网络投票系统 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2025 年 3 月 7 日 至 2025 年 3 月 7 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投 ...

Revenue and Profit Projections - The company expects to achieve operating revenue of between CNY 1,145.48 million and CNY 1,228.44 million for 2024, representing a year-on-year increase of CNY 131.45 million to CNY 214.40 million, or a growth of 12.96% to 21.14%[4]. - The projected net profit attributable to the parent company for 2024 is between CNY 700.40 million and CNY 771.90 million, an increase of CNY 405.78 million to CNY 477.29 million compared to the previous year, reflecting a growth of 137.73% to 162.00%[4]. - The expected net profit attributable to the parent company after deducting non-recurring gains and losses is projected to be between CNY 238.79 million and CNY 278.59 million, an increase of CNY 32.17 million to CNY 71.97 million, or a growth of 15.57% to 34.83%[4]. - The previous year's net profit attributable to the parent company was CNY 294.61 million, with a total profit of CNY 310.63 million[10]. - The company reported earnings per share of CNY 0.48 for the previous year[11]. Research and Development Investment - The company plans to invest between CNY 522.96 million and CNY 558.96 million in R&D for 2024, which is an increase of CNY 208.77 million to CNY 244.77 million, representing a growth of 66.45% to 77.91% compared to the previous year[5]. - The capitalized R&D expenses are expected to be between CNY 341.49 million and CNY 371.49 million, an increase of CNY 59.19 million to CNY 89.19 million, reflecting a growth of 20.97% to 31.59%[5]. Special Dividend and Performance Forecast - The company received a special dividend distribution of USD 6.24 million (approximately CNY 446.55 million) from its associate Numab Therapeutics, AG, positively impacting the 2024 operating performance[12]. - The performance forecast is based on preliminary calculations by the finance department and has not been audited by a registered accountant[9]. - The company does not foresee any significant uncertainties that could affect the accuracy of this performance forecast[13].

1 公司董事会秘书，其任职资格已经公司董事会提名委员会审查通过， 任期自公司董事会审议通过之日起至本届董事会届满之日止。 一、 董事会会议召开情况 鉴于刘彦丽女士因工作重心调整辞去董事会秘书一职，辞职后刘 彦丽女士继续担任公司总经理、董事职务。根据《中华人民共和国公 司法》等法律法规和《公司章程》规定，董事会同意聘任张琦先生为 三生国健药业（上海）股份有限公司（以下简称"公司"）第五 届董事会第三次会议于 2024 年 12 月 26 日以电话、电子邮件、专人 送达等方式发出,会议于 2025 年 1 月 3 日以通讯和现场结合方式召 开。本次会议应出席董事 7 人，实际出席会议董事 7 人。会议由董事 长 LOU JING 先生召集和主持。会议的召集和召开程序，符合《中华 人民共和国公司法》和《公司章程》的有关规定。 二、 董事会会议审议情况 证券代码：688336 证券简称：三生国健 公告编号：2025-002 （一）审议通过《关于聘任公司董事会秘书的议案》 三生国健药业（上海）股份有限公司 第五届董事会第三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏， ...

证券代码：688336 证券简称：三生国健 公告编号：2024-046 三生国健药业（上海）股份有限公司 关于召开 2024 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 三生国健药业（上海）股份有限公司（以下简称"公司"）已于 2024 年 10 月 23 日发布公司 2024 年第三季度报告，为便于广大投资 者更全面深入地了解公司 2024 年第三季度经营成果、财务状况，公 司计划于 2024 年 11 月 28 日上午 11:00-12:00 举行第三季度业绩说 明会，就投资者关心的问题进行交流。 一、 说明会类型 1 会议召开时间：2024 年 11 月 28 日(星期四)上午 11:00-12:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心视频直播和网络互动 投资者可于 2024 年 11 月 21 日(星期四)至 11 月 ...

Investment Rating - The report assigns a "Buy" rating to the company, with a target equity value of 16.604 billion yuan [1]. Core Insights - The company is focusing on the autoimmune sector, with a rich pipeline of innovative products that are gradually being commercialized, expected to lead to rapid revenue growth [1]. - The company has a strong sales capability, with three marketed products showing steady revenue growth, particularly benefiting from improved patient compliance and accessibility [1]. - The research pipeline includes 14 autoimmune projects, with several in advanced clinical stages, indicating a promising future for product approvals and market entry [1]. Summary by Sections Company Overview - The company is a pioneer in antibody drug development in China, with a focus on innovative monoclonal antibodies and a mature integrated platform for research, production, and sales [7]. - It has shifted its focus to the autoimmune sector by divesting oncology and ophthalmology assets to enhance core competitiveness and optimize product pipelines [8]. Marketed Products - **Yisaipu**: The first TNF-α inhibitor in China, showing a recovery in sales with a revenue of 570 million yuan in 2023, up 10.5% year-on-year [22]. - **Saiputing**: An innovative anti-HER2 monoclonal antibody for breast cancer, included in multiple treatment guidelines, enhancing its market presence [26][28]. - **Jianipai**: The only approved humanized anti-CD25 monoclonal antibody in China, with significant potential in kidney transplant rejection prevention [8]. Pipeline Development - The company has 14 autoimmune projects, including 6 in Phase III and 8 in Phase II clinical trials, indicating a strong focus on autoimmune diseases [18]. - Key products in development include SSGJ-608 for psoriasis, SSGJ-611 for atopic dermatitis, and SSGJ-613 for gout, all showing promising clinical results [19][20]. Financial Forecast and Investment Recommendations - The company is expected to achieve net profits of 655 million yuan, 291 million yuan, and 365 million yuan for 2024, 2025, and 2026 respectively, with a significant dividend income from an associate company in 2024 [1]. - The report emphasizes the potential for multiple products to achieve "First-in-Class" and "Best-in-Class" status, supporting the investment recommendation [1].

证券代码： 688336 证券简称：三生国健 公告编号：2024-045 三生国健药业（上海）股份有限公司 关于自愿披露公司获得《药物临床试验批准通知书》 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 近日，三生国健药业（上海）股份有限公司（以下简称"公司" 或"三生国健"）重组抗 BDCA2 人源化单克隆抗体注射液（研发代号： SSGJ-626）收到国家药品监督管理局（以下简称"国家药监局"）核 准签发的系统性红斑狼疮（SLE）和皮肤型红斑狼疮（CLE）临床试验 《药物临床试验批准通知书》。现将相关情况公告如下： 1 药品名称 重组抗 BDCA2 人源化单克隆抗体注射液 剂型 注射剂 申请事项 临床试验申请 申请人 三生国健药业（上海）股份有限公司 审批结论 经审查，2024 年 8 月 15 日受理的重组抗 BDCA2 人源化单 克隆抗体注射液符合药品注册的有关要求，同意本品开展成人 一、药品基本情况 | | 系统性红斑狼疮适应症临床试验。 | | | | | | | | | --- | -- ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected stock price increase of over 20% relative to the market benchmark within the next six months [11]. Core Views - The company's performance in the first three quarters of 2024 shows a revenue of 939 million yuan, representing a year-on-year growth of 28.6%, and a net profit attributable to shareholders of 233 million yuan, up 42.2% [1][4]. - The main products of the company have shown stable growth, with a total revenue of 778 million yuan in the first three quarters, reflecting a year-on-year increase of 19.34% [2]. - The company has a strong research and development pipeline, with significant progress in clinical trials for various indications, indicating efficient advancement in its product development [3]. Summary by Sections Financial Performance - For Q1-Q3 2024, the company reported a revenue of 939 million yuan (+28.6%) and a net profit of 233 million yuan (+42.2%), with Q3 alone contributing 343 million yuan (+35.6%) in revenue and 104 million yuan (+49.7%) in net profit [1][4]. - The projected net profits for 2024-2026 are 700 million yuan, 270 million yuan, and 340 million yuan respectively, with previous estimates being 250 million yuan, 240 million yuan, and 310 million yuan [4]. Product and R&D Insights - The company’s key products are expected to face price pressure due to expanded collection, but the introduction of pre-filled syringes is anticipated to enhance patient compliance and drive stable growth [2]. - The R&D expenses for the first three quarters reached 354 million yuan, an increase of 54.1%, with the R&D expense ratio remaining at a healthy level [2]. Pipeline Development - The company has made significant progress in its R&D pipeline, with multiple products in various stages of clinical trials, including completion of Phase III trials for certain indications and ongoing Phase III enrollments for others [3].

Group 1: Company Performance Overview - In the first three quarters of 2024, the company achieved a revenue of 939 million CNY, representing a year-on-year growth of 28.58% [2] - Major product revenue reached 778 million CNY, with a year-on-year increase of 19.34% [2] - The net profit attributable to shareholders was 233 million CNY, reflecting a year-on-year growth of 42.18% [2] - Research and development investment totaled 354 million CNY, up 54.07% year-on-year, with R&D expenses increasing by 41.50% [2] Group 2: Clinical Development Progress - The anti-IL-17A monoclonal antibody ("608") has completed Phase III clinical trials for moderate to severe plaque psoriasis [3] - The anti-IL-5 monoclonal antibody ("610") is currently enrolling patients in Phase III clinical trials for severe eosinophilic asthma [3] - The anti-IL-1β monoclonal antibody ("613") has completed Phase III trials for acute gouty arthritis [3] Group 3: Market Insights and Competitive Landscape - The domestic asthma prevalence rate among individuals aged 20 and above is 4.2%, equating to approximately 46 million asthma patients, with 8-10% classified as severe asthma [5] - The overall prevalence of hyperuricemia in China is 14%, affecting around 197 million people, with over 14.66 million diagnosed with gout [8] - The market for IL-1β treatments is competitive, with key players including the company and Jinsai Pharmaceutical [9] Group 4: Future Strategies and Focus Areas - The company plans to prioritize business development (BD) efforts in the coming year, focusing on large molecules through internal R&D and seeking licensing opportunities for small molecules [7] - The company aims to submit the NDA for the IL-17A project by the end of the year, positioning itself as the third domestic player in this space [4]